Previous 10 | Next 10 |
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to it...
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2021 financial and operating results after the market clo...
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of a public offering of 20,700,000 shares of Marava...
Maravai LifeSciences (MRVI) has priced its upsized public offering of 18M Class A shares (from 15M), offered by certain selling stockholders at $31.25/share.The offering was upsized from 15M shares.Underwriters' over-allotment is an additional 2.7M shares, upsized from 2.25M shares. Maravai w...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of an upsized public offering of 18,000,000 shares ...
Maravai LifeSciences Holdings (MRVI) provides preliminary results for the quarter ended March 31, 2021. The Company expects to report total revenues of ~$148M, +50% Q/Q and ahead of previous guidance of sequential revenue growth of 30% to 35%. The average analyst expectation is $135.36M.Nucle...
Maravai LifeSciences Holdings (MRVI) has commenced public offering of 15M shares of Class A common stock offered by certain selling stockholders.Underwriters' over-allotment is an additional 2.25M shares. Maravai will not receive any proceeds from sale of shares by the selling stockholders. M...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the commencement of a public offering of its Class A common sto...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today provided preliminary unaudited revenue and Income from Operati...
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTech...
News, Short Squeeze, Breakout and More Instantly...
Maravai LifeSciences Holdings Inc. Company Name:
MRVI Stock Symbol:
NASDAQ Market:
Maravai LifeSciences Holdings Inc. Website:
2024-07-25 20:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. - Increased the sc...